Dexcom Inc. Stock
€75.74
Your prediction
Financial data and news for DexCom
sharewise wants to provide you with the best news and tools for DexCom, so we directly link to the best financial data sources.
Financials
News
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the
DexCom (DXCM) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2024 Earnings CallFeb 13, 2025, 4:30 p.m. ET
Operator
Source Fool.com
DexCom: Revenue Up, EPS Misses Mark
DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue
Should You Buy DexCom Stock Before Feb. 13?
DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels.
However, the rising popularity of GLP-1 drugs, which are
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to
Got $2,000? 2 Top Growth Stocks to Buy and Hold for Years
The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the performance of many top stocks reflects this reality. However, a share price
2 Healthcare Stocks to Buy Hand Over Fist in January
Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period. Instead, as long-term investors know, the key is to
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
The past year was a great one for the stock market as a whole, but there were plenty of companies that didn't do well in 2024. Shares of Celsius Holdings (NASDAQ: CELH), DexCom (NASDAQ: DXCM), and
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights:
-
Revenue grew 12% year-over-year to
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to
Dexcom Appoints Jon Coleman as Chief Commercial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across
Dexcom Appoints Renée Galá to Board of Directors
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.
Ms. Galá is an accomplished
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th.
The
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights:
-
Revenue grew 8%